Slingshot members are tracking this event:

FDA clears Biohaven's Investigational New Drug Application For BHV-4157 and Portage To Hold Investor Conference Call to Provide Business Update

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

BHVN Community voting in process

Additional Information

Additional Relevant Details FDA has completed its review of the Biohaven’s investigational drug application (IND) for BHV-4157 filed on May 31, 2016 and informed Biohaven that clinical trials in humans may proceed. The IND for BHV-4157 includes plans for a pivotal trial in the indication of Spinocerebellar Ataxia (SCA), a rare and debilitating neurodegenerative disorder with no currently approved treatment. Biohaven plans to initiate a pivotal Phase III clinical trial in SCA before the end of the year.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 05, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Bhv-4157, Glutamate, Bhv-0223, Spinocerebellar Ataxia